IHC evaluation of trans-iliac bone marrow biopsies, obtained at baseline and after six weeks under cabozantinib treatment from patients with PCa, revealed relative increases in expression levels of pFGFR1, YAP, and TBX5, therefore supporting the activation of the Hippo pathway as part of the molecular mechanism of acquired resistance to VEGF/MET-targeted treatment [120]. The gene discussed is YAP1; the disease is posterior cortical atrophy.